GR3035050T3 - Method of preparing a viral vector by homologous intermolecular recombination - Google Patents
Method of preparing a viral vector by homologous intermolecular recombinationInfo
- Publication number
- GR3035050T3 GR3035050T3 GR20000402737T GR20000402737T GR3035050T3 GR 3035050 T3 GR3035050 T3 GR 3035050T3 GR 20000402737 T GR20000402737 T GR 20000402737T GR 20000402737 T GR20000402737 T GR 20000402737T GR 3035050 T3 GR3035050 T3 GR 3035050T3
- Authority
- GR
- Greece
- Prior art keywords
- preparing
- viral vector
- vector
- intermolecular recombination
- particle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9414470A FR2727689A1 (fr) | 1994-12-01 | 1994-12-01 | Nouveau procede de preparation d'un vecteur viral |
PCT/FR1995/001590 WO1996017070A1 (fr) | 1994-12-01 | 1995-12-01 | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3035050T3 true GR3035050T3 (en) | 2001-03-30 |
Family
ID=9469390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20000402737T GR3035050T3 (en) | 1994-12-01 | 2000-12-12 | Method of preparing a viral vector by homologous intermolecular recombination |
Country Status (13)
Country | Link |
---|---|
US (3) | US6110735A (el) |
EP (1) | EP0742834B9 (el) |
JP (1) | JP3989541B2 (el) |
AT (1) | ATE196507T1 (el) |
AU (1) | AU707208B2 (el) |
CA (1) | CA2182303C (el) |
DE (2) | DE69518910D1 (el) |
DK (1) | DK0742834T4 (el) |
ES (1) | ES2150595T5 (el) |
FR (1) | FR2727689A1 (el) |
GR (1) | GR3035050T3 (el) |
PT (1) | PT742834E (el) |
WO (1) | WO1996017070A1 (el) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
US6720140B1 (en) * | 1995-06-07 | 2004-04-13 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
FR2761689B1 (fr) | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
WO1998056937A2 (en) * | 1997-06-09 | 1998-12-17 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
EP1015620B1 (en) | 1997-09-23 | 2005-08-31 | Genvec, Inc. | Dual selection cassette and plasmids containing same |
CN101125873A (zh) * | 1997-10-24 | 2008-02-20 | 茵维特罗根公司 | 利用具重组位点的核酸进行重组克隆 |
WO1999021977A1 (en) * | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
EP2119788A1 (en) | 1999-03-02 | 2009-11-18 | Life Technologies Corporation | Compositions and methods for use in recombinational cloning of nucleic acids |
CA2394099A1 (en) * | 1999-12-07 | 2001-06-14 | Genethon Iii | Adenovirus vectors for the transfer of genes in targeted cells |
NZ530816A (en) * | 1999-12-10 | 2005-10-28 | Invitrogen Corp | Use of multiple recombination sites with unique specificity in recombinational cloning |
ES2394877T3 (es) * | 2000-08-14 | 2013-02-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
AU2002212507A1 (en) * | 2000-11-10 | 2002-05-21 | Astrazeneca Ab | Vector |
GB0027501D0 (en) * | 2000-11-10 | 2000-12-27 | Astrazeneca Ab | Vector |
AU2002357267A1 (en) * | 2001-12-14 | 2003-06-30 | President And Fellows Of Harvard College | Immune related neuronal receptors and therapeutic uses thereof |
US7521242B2 (en) * | 2003-05-09 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids |
EP2404931A1 (en) * | 2003-07-02 | 2012-01-11 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
AU2004257935B2 (en) | 2003-07-21 | 2009-11-19 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
EP1648931B1 (en) | 2003-07-21 | 2011-02-09 | Transgene S.A. | Multifunctional cytokines |
EP2287341B1 (en) | 2003-12-01 | 2013-02-13 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
US7674621B2 (en) | 2004-05-21 | 2010-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Plasmids and phages for homologous recombination and methods of use |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
SI2484375T1 (en) | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | A vaccine composition comprising a synthetic adjuvant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
DK2118292T3 (da) | 2007-01-30 | 2011-10-24 | Transgene Sa | Papillomavirus E2-polypeptid der anvendes til vaccination |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
US20110287089A1 (en) | 2009-01-13 | 2011-11-24 | Karola Rittner | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
BRPI1006901A2 (pt) | 2009-01-20 | 2016-02-16 | Transgène S A | método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue |
HUE026194T2 (en) | 2009-03-24 | 2016-05-30 | Transgene Sa | Biomarker for checking patients |
RU2555340C2 (ru) | 2009-04-17 | 2015-07-10 | Трансжене Са | Биомаркер для мониторинга пациентов |
WO2010141861A1 (en) | 2009-06-05 | 2010-12-09 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US20110015256A1 (en) * | 2009-07-16 | 2011-01-20 | Ihab Mamdouh Ishak Sadek | Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions |
EP2461826A2 (en) | 2009-08-07 | 2012-06-13 | Transgene SA | Composition for treating hbv infection |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP3563834A1 (en) | 2012-02-07 | 2019-11-06 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
AU2013262691B2 (en) | 2012-05-16 | 2018-12-20 | Immune Design Corp. | Vaccines for HSV-2 |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
KR102392974B1 (ko) | 2016-05-16 | 2022-05-02 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | Tlr 작용제를 함유하는 제제 및 사용 방법 |
AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
EP3516064A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New promoters |
US10626414B2 (en) | 2016-09-20 | 2020-04-21 | Boehringer Ingelheim Vetmedica Gmbh | Swine influenza vaccine |
CN109715219B (zh) | 2016-09-20 | 2024-03-01 | 勃林格殷格翰动物保健有限公司 | 犬腺病毒载体 |
WO2018054837A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New ehv insertion site orf70 |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
CA3044074A1 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
CA3061206A1 (en) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
IL270271B2 (en) | 2017-05-02 | 2023-03-01 | Immunomic Therapeutics Inc | LAMP structures containing cancer antigens |
WO2019051149A1 (en) | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE |
EP3793595A1 (en) | 2018-05-15 | 2021-03-24 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising allergens |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
WO2021077051A1 (en) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | calr and jak2 mutant-based vaccines and their uses |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
EP4135757A1 (en) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
US5582362A (en) * | 1995-03-31 | 1996-12-10 | Johnson; John R. | Center feed toilet paper dispenser |
-
1994
- 1994-12-01 FR FR9414470A patent/FR2727689A1/fr active Granted
-
1995
- 1995-12-01 DK DK95941755T patent/DK0742834T4/da active
- 1995-12-01 PT PT95941755T patent/PT742834E/pt unknown
- 1995-12-01 WO PCT/FR1995/001590 patent/WO1996017070A1/fr active IP Right Grant
- 1995-12-01 AT AT95941755T patent/ATE196507T1/de active
- 1995-12-01 DE DE69518910A patent/DE69518910D1/de not_active Expired - Lifetime
- 1995-12-01 CA CA002182303A patent/CA2182303C/fr not_active Expired - Lifetime
- 1995-12-01 ES ES95941755T patent/ES2150595T5/es not_active Expired - Lifetime
- 1995-12-01 AU AU43068/96A patent/AU707208B2/en not_active Expired
- 1995-12-01 DE DE69518910T patent/DE69518910T3/de not_active Expired - Lifetime
- 1995-12-01 EP EP95941755A patent/EP0742834B9/fr not_active Expired - Lifetime
- 1995-12-01 JP JP51834696A patent/JP3989541B2/ja not_active Expired - Lifetime
- 1995-12-01 US US08/682,794 patent/US6110735A/en not_active Expired - Lifetime
-
1999
- 1999-12-21 US US09/467,952 patent/US6281000B1/en not_active Expired - Lifetime
-
2000
- 2000-12-12 GR GR20000402737T patent/GR3035050T3/el unknown
-
2001
- 2001-08-27 US US09/938,491 patent/US7067310B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2182303A1 (fr) | 1996-06-06 |
EP0742834B2 (fr) | 2005-08-03 |
EP0742834B9 (fr) | 2005-12-28 |
ATE196507T1 (de) | 2000-10-15 |
FR2727689B1 (el) | 1997-02-28 |
EP0742834A1 (fr) | 1996-11-20 |
EP0742834B1 (fr) | 2000-09-20 |
DK0742834T4 (da) | 2005-08-22 |
DE69518910T4 (de) | 2006-02-09 |
AU707208B2 (en) | 1999-07-08 |
ES2150595T5 (es) | 2005-12-01 |
US6281000B1 (en) | 2001-08-28 |
DE69518910D1 (de) | 2000-10-26 |
JPH09509330A (ja) | 1997-09-22 |
DE69518910T2 (de) | 2001-03-29 |
DE69518910T3 (de) | 2006-07-13 |
AU4306896A (en) | 1996-06-19 |
FR2727689A1 (fr) | 1996-06-07 |
PT742834E (pt) | 2001-03-30 |
US7067310B2 (en) | 2006-06-27 |
WO1996017070A1 (fr) | 1996-06-06 |
DK0742834T3 (da) | 2001-01-29 |
US20020090715A1 (en) | 2002-07-11 |
JP3989541B2 (ja) | 2007-10-10 |
US6110735A (en) | 2000-08-29 |
ES2150595T3 (es) | 2000-12-01 |
CA2182303C (fr) | 2005-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3035050T3 (en) | Method of preparing a viral vector by homologous intermolecular recombination | |
IL111734A0 (en) | Compositions for the preparation of in vivo therapeutic products | |
HU9603155D0 (en) | Papillomavirus vaccines | |
CZ63995A3 (en) | Virus vectors and their use in gene therapy | |
WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
AU2790292A (en) | Viral recombinant vectors for expression in muscle cells | |
MY111196A (en) | Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
IL112289A0 (en) | Composition containing nucleic acids, preparation and use | |
HU9201712D0 (en) | A mammalian cytokine, il-11 | |
GB2335194A (en) | Notch | |
GB2335426B (en) | EHV-1 Vectors | |
ES8707488A1 (es) | Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona | |
HK1002284A1 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
EP0452894A3 (en) | Human cells for the high expression of genes inserted in episomal recombinant dna, their preparation and their use | |
HU9600432D0 (en) | Novel tripeptides useful in immune and cns therapy | |
GEP20012489B (en) | Use of Natural Human α-Interferon | |
TW374085B (en) | Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use | |
ES8704903A1 (es) | Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido. | |
MX9708111A (es) | Lipidos cationicos para terapia genica. |